A Man with Terminal Glioblastoma Was Given 12–15 Months to Live.

Why It Matters

Broader approval of Anktiva could dramatically extend survival for patients with aggressive cancers, reshaping oncology treatment standards and accelerating immune‑cell therapy adoption.

Key Takeaways

• Patient with terminal glioblastoma shows normal scan after Anktiva.
• Dr. Patrick Soon‑Shiong claims Anktiva activates natural killer cells.
• FDA approval limited to bladder cancer despite broader trial success.
• Over 1,000 trial participants report extended survival across cancers.
• Media push aims to accelerate regulatory clearance for Anktiva.

Summary

The video follows a man diagnosed with terminal glioblastoma, given a 12‑15‑month prognosis, who is now on his fourth dose of Anktiva and whose latest MRI returned a normal result. Dr. Patrick Soon‑Shiong, the billionaire surgeon who created the drug, has been touring talk shows to champion its broader use.

Anktiva is described as a therapy that activates natural‑killer (NK) cells to target and destroy cancer cells. Clinical data from roughly a thousand trial participants suggest extended survival in glioblastoma, breast, lung and pancreatic cancers, yet the FDA has approved the drug only for a niche bladder‑cancer indication.

Dr. Soon‑Shiong is quoted calling Anktiva “a universal treatment” and “one of the most groundbreaking cancer therapies ever,” adding that delaying access is “a crime.” The patient’s scan serves as a tangible example of the drug’s potential impact.

If regulators expand approval, Anktiva could reshape treatment paradigms for aggressive tumors, offering new hope and prompting faster adoption of immune‑cell‑based therapies across oncology.

Original Description

After four injections of a therapy called Anktiva, his latest scan came back normal.

The treatment has been studied for more than a decade and has shown promise across multiple cancer types, yet it's only approved for a narrow form of bladder cancer.

Should potentially life-saving treatments move through the approval process faster for patients with no other options?